Physician profile
Eric A Ravitz
NPI 1215034681
$2,496.52
in general payments reported to CMS, 2019-2025
30 companies · $584 in 2025
The $584 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $149 · 2021: $303 · 2022: $332 · 2023: $297 · 2024: $412 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,293.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $574.45 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $451.83 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $270.68 | 2019-2025 | Trelegy Ellipta, Shingrix, Penmenvy |
| Vanda Pharmaceuticals INC. | $172.47 | 2025 | Fanapt |
| Pfizer INC. | $124.71 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $102.71 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.35 | 2019-2021 | |
| Exact Sciences Corporation | $80.74 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $54.06 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $49.78 | 2023-2024 | Spravato |
| Neurocrine Biosciences, INC. | $41.60 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.79 | 2025 | Caplyta |
| Organon LLC | $39.23 | 2021-2024 | |
| Allergan, INC. | $37.70 | 2019 | |
| Alkermes, INC. | $36.96 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $36.13 | 2019-2024 | Mounjaro |
| Si-Bone, INC. | $36.00 | 2025 | |
| Sunovion Pharmaceuticals INC. | $31.03 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.58 | 2019-2021 | |
| Gilead Sciences, INC. | $25.18 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $24.68 | 2021 | |
| Exeltis, USA INC. | $23.24 | 2024 | Slynd |
| Biohaven Pharmaceuticals, INC. | $21.02 | 2021 | |
| Ucb, INC. | $17.75 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.57 | 2023 | |
| Astellas Pharma US INC | $15.16 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.79 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.19 | 2022 | |
| Novo Nordisk INC | $13.16 | 2023 | |
| Coopersurgical, INC. | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Ravitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.